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IT has previouslv beeii suggested that the oncolytic reactioii that occurs wheii
Ehrlich ascites carcinoma cells are brought into coiitact with fresh humaii serum
is due to the complement in the serum acting on the cells that have been sensitised
in vivo (Hartveit, I965). The cells, in this case, have beeii sensitised as a result
of a homograft reaction oii the part of the genetically iiicompatible host. The
Bergen A4 ascites carcinoma (Hartveit, 1964), on the other hand, arose in a
strain A/Sii mouse kept at this Institute aiid is kept bv serial transplantatioii
in geiietically compatible mice, i.e. mice that are compatible with the host of
origin. So in this case the tumour cells caniiot become sei-isitised as the res-Litt
of a homograft reaction. If thev show signs of sensitisation some other meeli-
aiiism must be at work.
Previous studies oii the oiicolytic reactioii reported in tiie literature (Hartveit,
1965a) have, with one exception (Willheim and Ivy, 1959), used either trans-
planted mouse tumours growing as homografts or cells in tissue culture (Bolande,
1960). In iio case has a tumour transplanted to a geiieticallv compatible host
beeii used. The following experiments were therefore carried out on such a
tumour, the Bergen A4 ascites carcinoma, to see whether the cells were seiisitised
or iiot. Firstly, the reactioii of these tumour cells to fresli human serum w'as
compared to that of Ehrlich ascites carcinoma cells, ai-id secoiidly, fresh humaii
serum was adsorbed with Bergeii A4 ascites carcinoma cells to see if the cells
lArere capable ofadsorbing the oncolytic and haemolytic activity, i.e. complemeilt
(Hartveit, 1965a) from the serum. As the results of repeated tests were similar
oiilv specimei-i experiments will be reported here.
MATERIAL A-ND METHODS
Jlice.-Mice of the closed coloiiv kept at this Iiistitute (Rartveit, 1961) aiid
Fl hybrids of these mice (y) and mice of straiii A,,/'Sii (3) m-e're iised. All the mice
-xvere approximately 4 moiiths old.
Tumour&-The Ebrlich ascites carciiioma transplaiited iii mice of the closed
colonv. aiid the Bergen A4 ascites carcinoma transplanted in the F, hybrids. were
itsed. Eleven-day intraperitoiieal traiisplants of both tumours were used in the
first experiment. Seventeen-day Bergei-i A4 ascites carciiioma cells aiid 8-day
cells from the iiext transplaiit generatioii were -tised in the secoiid experimeiit.
Sera.-Fresh h-Limaii serum was obtained by courtesv of the medical aiid
iiursing staff from patieiits in the m-ards of Haukelaiid Hospital, Bergeii. Sera
'were stored at 20' C. m-ithiii 3 hours of bleeding.
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Sen,siti8ed 8hee cell-8.-Sheep erythrocvtes aiid rabbit anti-sheep serum were p I
obtained from the Gade Institute Departmeiit of Microbiology, by courtesv of
Professor Vogelsang. The cells were sensitised as described previously (Hart-
veit, 1965a).
EXPERIMENTAL PROCEDtTRE
Experiment I.-A I in 20 suspension of whole tumour ascites from the Elirlich
ascites carcinoma in physiological saline was made up. A similar suspeiisioii of
Bergen A4 ascites carcinoma cells was also made up. Tumour cell counts on these
two suspensions showed good agreement and all the tumour cells appeared viable
(Schrek's method-1936). Twelve consecutive fresh human sera were used.
Paired tests were set up in which one part of fresh human serum was mixed with
one part of the Ehrlich ascites carcinoma cell suspensioii and with one part of the
Bergen A4 cell suspension. Controls were set up with saline in place of serum.
Wet preparatioiis were made and the results read microscopically (cutting
down the aperture oii a bright field condenser) after 30 minutes at 22' C. Lysis
was recorded as absent (O per cent), partial (50 per cent) or complete (100 per
ceiit).
Experiment II.-Fresh human serum was adsorbed for four hours at 4' C.
with 8-day Bergen A4 ascites carcinoma cells and also with 17-day Bergen A4
ascites careiiioma cells. The adsorbed sera, in both cases, were tested for both
haemolytic and oiicolytic activity, using sensitised sheep cells and 8-day Bergeii
A4 ascites carcinoma cells, respectively. (For details of method see Hartveit,
1965a.)
RESULTS
Experiment I.-Fig. I compares the lytic ability of 12 human sera oii cells
of the Bergen A4 ascites carcinoma and cells of the Ehrlich ascites carciiioma.
and shows that the results were directly comparable in all but one case. Six
sera were noii-oncolvtic in both systems; one gave complete lysis in both systems-,
foitr gavepartial lvsis. The exception, serum 8, gavepartiallysis with the Bergeii
A4 ascites carcinoma cells and no lysis with the Ehrlich cells. Coiitrol cells
showed i-io Ivsis.
TABLE I.-The Effect of Ad,8orption with Bergen A4 Ascite.8 ('arcinoma Ce118 on
the Haemolytic and Oncolytic Activity of Fresh Human Serum
Lytic activity of a(isorbed serum
in
Fi-esli liuiiian seruiii A
adsorbed* with Haemolytic, system OncoIN-tic svsteni
8-day Bergen A4 cells +
17-day Bergen A4 cells
Control (unadsorbed serum) +
* For 4 hours at 4' C.
Experiment II.-Table I shows the effect ofadsorption of fresh human serum
(that was both haemolytic and oncolytic) with 8-day and with 17-day Bergei-i
A4 ascit-es carcinoma cells. Adsorption with 8-day cells resulted in loss of onco-9
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lytic but not ofhaemolytic ability. On the other hand, adsorption with 17-day
cells removed both these properties.
DISCUSSION
Experiment I shows that the lytic action of fresh human serum on Ehrlich
ascites carcinoma cells and Bergen A4 ascites carcinoma ceRs is essentially com-
parable : a serum that is highlylytic to Ehrlich cells beinghighlylytic to Bergen
A4 cells, and non-lytic sera being non-lytic in both systems. Now as mentioned
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FIG. I.-Comparison ofoncolytic action of 12 hunian sera on two ascitic tumours.
* Control cells in saline.
previously, the cells of the Ehrlich ascites carcinoma are homografted cells and
maywellhavebeensensitisedbyantibodysupphedbythehost(Hartveit, 1965a,b).
On the other hand, cells of the Bergen A4 ascites carcinoma are grown in a
genetically compatible system, so no homograft reaction is to be expected.
There are, however, two possibilities that must be considered that would
result in anantigenic difference between host and tumour in this system. Firstly,
a mutation may have occurred in the tumour during its serial transplantatioii.
However, such mutations usually take the form of loss rather than gain in anti-
genicity (Hauschka and Amos, 1957), and loss of antigenicity would be of no
account in this connection. In addition this tumour showed evidence of antigenic
difference from its host as early as its third transplant generation (Hartveit,
1964) and had only reached its 10th transplant generation at the time of the724 F. HARTVEIT
present experimeiit. During this time its characteristics oii traiisplaiitatioii
liave i-iot changed, so there is no direct evidence that mutatioii has occurred.
The second possibilitv that would make the tumour antigenically different
from its host is that during the process ofmaligiiant change the cells, by mutation
or otherwise, may have gained a tumour specific antigen. This explanation is
supported by the finding mentioned above, that evidence of antigenic difference
was available as early as the third transplant generation in this tumour, and
possibly earlier in other similar cases (see Hartveit, 1964, re Klein, 1951). In
addition preliminarv tests of the action of fresh human serum were carried out
oii the first ascitic generation (4th transplaiit geiieration) ofthis tumour and these
tests also showed lysis.
If the findings in experiment I cannot be explained on the basis of antibody suppliedbythe host in response to anantigenic difference between host andtumour,
oiie would have to postulate that the lytic activity ofthe hiiman serum on Bergen A4 ascites careiiioma cells is due to the presence of heteropbil antibody in the
human serum. Now with the Ehrlich ascites carcinoma system it has been shown
that this is not so (Hartveit, 1965b) ; the lytic action of human serum in that
system is due to its complement content alone. It would be a remarkable co-
incidence if the variation in complement content of the different sera shown,
expressed as the oncolytic ability of the sera, in Fig. 1, paralleled their heterophil antibody content so well. Furthermore the mice used for transplantation of the
two tumours were different, the Ehrlich ascites carcinoma being transplanted in mice ofthe closed colony and the Bergen A4 in the F, hybrids. So the reaction
ofthe mice could be expected to differ. Yet in both cases the results were similar.
This suggests that some factor in the serum, rather than one produced by the
mouse, is the limiting factor in both cases. So, all in all, it seems more likelv
that the Bergen A4 cells-like the Ehrlich cells-have been sensitised in vivo
aiid are merelv reacting to the complement conteiit of the human se'rum.
This view is supported by the results of experiment 11. These results are
similar to the adsorption studies reported previously with the Ehrlich ascites
carcinoma (Hartveit, 1965a). These latter studies showed that cells from an earlv
transplant could adsorb enough complement from human serum to hamper oiicolysis, but iiot enough to prevent the more sensitive haemolytic reaction.
Oi-i the otlier hand cells from a late transplant, that had had more time to become
seiisitised in vivo, could adsorb both the haemolytic and the oncolytic activity. The present experimeiit has shown that cells from an early transplant of the
Bergen A4 ascites carcinoma, like those from an early transplant of the Ehrlich
ascites carcinoma, cai-i adsorb the oncolytic but not the haemolytic activity from
human serum. Cells from a late transplant can, in both cases, adsorb both the
oiicolytic and the haemolytic activity. As was the case in the previous experi- meiit with the Ehrlich ascites carcinoma, the difference in the tumour cells used
for adsorption lies in the time that had been available for in vivo sensitisation.
These findin s caiinot be explained on the basis of heterophil aiitibodv in the
serum.
In the case of the Ehrlich ascites carcinoma the antibody produced in vivo
that is active in the oncolytic reaction cannot be said to be tumour specific. However, the similarity in the findings with this tumour and the Bergen A4
ascites carcinoma suggests that tumour specific antibody may be responsible for
the oncolvtic reactioii in the latter case.LYTIC ACTION OF FRESH HUMAN SERtTM 72115)
SUMMARY
The reactioii of the cells of the Ehrlich ascites careiiioi-iia aiid of the Bergeil
A4 ascites carcinoma to fresh human serum was compared and foulid to be similar.
In addition Bergen A4 ascites carcinoma cells were able to adsorb both the onco-
lytic and the haemolytic activity from fresh human serum. It is suggested that
these results indicate that the Bergeii A4 ascites carciiioma cells, as well as the
Ehrlich ascites carcinoma cells, have beeii sensitised -in iiivo. If this is so the
aiitibody concerned in the Bergeii A4 system (in which the tumour was trans-
planted in genetically compatible mice) could have beeii produced in response
to a tumour specific antigeii in the transplaiited tumour.
I would like to thank Professor E. Waaler, Head of this Institute, for the
ijiterest he has shown in this work.
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